Navigation Links
Pharmacyclics Reports Results for Six and Three Months Ended December 31, 2012
Date:2/14/2013

nt with Janssen, total amounts in excess of the annual cap ("Excess Amounts") plus interest may not exceed $225 million.

The Company has recognized the Excess Amounts as a reduction to operating expenses in the current year as the Company's repayment of the Excess Amounts to Janssen is contingent and would become payable only after the third profitable calendar quarter for the product under the collaboration. Further, the Excess Amounts shall be reimbursable only from the Company's share of future full calendar quarter pre-tax profits (if any) after the third profitable calendar quarter for the product under the collaboration.

For the calendar year ended December 31, 2012, the Company's total share of collaboration expenses under the Agreement was $68.1 million. As of December 31, 2012, total Excess Amounts totaled $18.1 million, of which during the quarter ended December 31, 2012, $17.3 million was recorded as a reduction to research and development expense and $0.8 million was recorded as a reduction to general and administrative expense.

GAAP operating expenses were $40.6 million for the six months ended December 31, 2012, compared to $30.6 million for the six months ended December 31, 2011. Included in operating expenses for the six months ended December 31, 2012 is the $18.1 million reduction to operating expenses for Excess Amounts.

GAAP operating expenses were $16.7 million for the quarter ended December 31, 2012, compared to $16.0 million for the quarter ended December 31, 2011 and $23.9 million for the quarter ended September 30, 2012. Included in operating expenses for the quarter ended December 31, 2012 is the $18.1 million reduction to operating expenses for the Excess Amounts.

At December 31, 2012, the Company had cash, cash equivalents and marketable securities of $317.1 million, compared with $203.6 million at June 30, 2012. In addition, as of December 31, 2012, the Company had $26.6 million receivable from Jansse
'/>"/>

SOURCE Pharmacyclics, Inc.
Copyright©2012 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6 7 8 9 10 11 12 13 14

Related biology technology :

1. Pharmacyclics Reports Fiscal 2013 First Quarter Financial Results and Multiple PCI-32765 Presentations at the 54th American Society of Hematology Annual Meeting
2. Discovery Labs Reports Third Quarter Financial Results and Progress on Lead Programs
3. Verenium Reports Financial Results for the Third Quarter and Nine Months Ended September 30, 2011
4. Interleukin Genetics Reports Third Quarter 2011 Financial Results
5. Cell Therapeutics, Inc. Reports Results of Annual Meeting of Shareholders
6. Nile Therapeutics Reports 2011 Third Quarter Financial Results
7. Pharmasset Reports Fiscal Year End 2011 Financial Results
8. Palatin Technologies, Inc. Reports First Quarter Fiscal Year 2012 Results; Teleconference and Webcast to be held on November 15, 2011
9. SeraCare Reports Fiscal Year 2011 and Fourth Quarter Financial Results
10. WaferGen Reports Third Quarter 2011 Financial Results and Announces New Commercialization Strategy
11. Hadasit Bio-Holdings Ltd. Reports Significant External Financing for Portfolio Companies
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:7/1/2015)... Isagenix International, a leading global health and ... Silver, and three Bronze Stevie® Awards at the 2015 ... Chicago this month.The American Business Awards ... in the U.S. "Winning is a ... leaders, cultivating talent, creating a unified team, and crafting ...
(Date:7/1/2015)... , July 1, 2015  UCB, a ... ), a global leader in designing, transforming, and ... Innovation Award in recognition of their close collaboration ... in UCB,s global business services (GBS) finance organization. ... providers and clients that work together effectively to ...
(Date:6/30/2015)... 2015  NASA astronaut Kjell Lindgren , who is ... first mission to the International Space Station , will ... a.m. EDT Tuesday, July 7. Lindgren will participate ... Russia . The interviews will be preceded at ... mission training. To schedule an interview, media must ...
(Date:6/30/2015)... Church, VA (PRWEB) , ... June 30, 2015 ... ... and strategy services to the federal government, announced in a paper published this ... scientists uncovered a potential problem with the diagnostic techniques currently used to detect ...
Breaking Biology Technology:Isagenix Earns Nine American Business Awards 2Isagenix Earns Nine American Business Awards 3UCB and Genpact Receive Aecus Innovation Award for Success in Global Business Services 2UCB and Genpact Receive Aecus Innovation Award for Success in Global Business Services 3UCB and Genpact Receive Aecus Innovation Award for Success in Global Business Services 4UCB and Genpact Receive Aecus Innovation Award for Success in Global Business Services 5NASA Astronaut Preps for First Space Station Mission, Available for Media Interviews 2Noblis and Government Scientists Identify New Genomic Signatures of Ebola Using Whole Genomic Sequencing and Innovative BioVelocity Analytics Tool 2Noblis and Government Scientists Identify New Genomic Signatures of Ebola Using Whole Genomic Sequencing and Innovative BioVelocity Analytics Tool 3Noblis and Government Scientists Identify New Genomic Signatures of Ebola Using Whole Genomic Sequencing and Innovative BioVelocity Analytics Tool 4
... Inc. (Nasdaq: ITMN ) today announced that five ... the company,s research programs related to the hepatitis C virus ... Meeting of the European Association for the Study of the ... abstracts are expected to be available at www.easl.ch . ...
... ANNAPOLIS, Md., March 18 The following event was announced ... , WHAT: We Work for Health of ... health, academia, education, labor and business that will discuss the ... important to the survival and growth of medical innovation in ...
... to assess aspirin effectDENVER, March 18 Corgenix ... developer and marketer of diagnostic test kits, has ... March 29 - 31 at the American College ... annual meeting will take place in Orlando, Fla., ...
Cached Biology Technology:InterMune to Present Abstracts on HCV Protease Inhibitor ITMN-191 and HCV Development Program at the EASL Meeting 2InterMune to Present Abstracts on HCV Protease Inhibitor ITMN-191 and HCV Development Program at the EASL Meeting 3Maryland Business, Academic and Biopharma Groups Underscore Commitment to Medical Innovation, Finding Cures and Supporting the Economy 2Corgenix to Exhibit AspirinWorks(R) Test at ACC.09 2Corgenix to Exhibit AspirinWorks(R) Test at ACC.09 3
(Date:6/26/2015)... ATL Technology, LLC, a top provider of electromechanical ... use solutions, headquartered in Springville, Utah , ... California corporation with locations in Santa ... Rica ). This acquisition will incorporate MedConx,s ... ATL Technology,s existing facility in Costa Rica ...
(Date:6/24/2015)... 2015 The biologics safety testing market is ... the market include growth of the pharmaceutical and biological ... Over the years, the number of drug approvals in ... the FDA approved 225 drug applications and Health Canada ... Europe accounted for 3,822 of the pharmaceutical ...
(Date:6/24/2015)... , June 24, 2015 Biometry authentication ... emerging biometric password solution one face in. ... one face in, entering the expanding ... and affordable multifactor-authentication biometric answer to the password ... provided in partnership with KeyLemon, one face in ...
Breaking Biology News(10 mins):ATL Technology Announces Acquisition of MedConx, Inc. and Expanded Global Footprint 2Biological Safety Testing Market by Application, Product, & Test - Global Forecast to 2019 2Biological Safety Testing Market by Application, Product, & Test - Global Forecast to 2019 3Biological Safety Testing Market by Application, Product, & Test - Global Forecast to 2019 4KeyLemon Announces Partnership With Biometric Password Solution onefacein 2
... "At the dawn of the 21st century, we are faced with ... world has grown at a rapid pace, turning the demand for ... Gebisa Ejeta (winner of the world food prize 2009) who is ... held in Lancaster, UK, 13 15th September 2010. ...
... Tenn., Sept. 9, 2010 -- Exemplary efforts to "go ... a 2010 Federal Energy & Water Management Award and ... of the lab,s Sustainable Campus Initiative. The ... Management Program recognized ORNL for its outstanding achievements in ...
... SEPTEMBER 9, 2010 The American Society of Agronomy ... Awards Ceremony on Nov. 2 during the scientific society,s ... The annual awards are presented for outstanding contributions to ... , Alan Blaylock, Agrium Advanced Technologies ...
Cached Biology News:ORNL wins 2 awards for sustainability program 2American Society of Agronomy announces award recipients 2American Society of Agronomy announces award recipients 3American Society of Agronomy announces award recipients 4
Identify and characterize Phosphoinositide (PI(4,5)P2) binding...
... These skirted micro test tubes are used ... polypropylene, these tubes have uniform walls for ... with separate O-ring screw caps. The O-rings ... have an operating range from -55 to ...
... Antibody Coated CELlulose) was developed in the ... Kent, one of the earliest commercial pioneers ... the product range in 1987. Sac-Cel rapidly ... developing their own "in house" radioimmunoassays, and ...
Determine relative degree of protein binding to phosphoinositides...
Biology Products: